Last Update:
February 11, 2008
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader .
Perinatal data are integrated with Perinatal Conference Data in the
Perinatal Data Page. Pediatric data are integrated with
Pediatric Conference Data in the Pediatric Data Page
-
Nelfinavir Monotherapy Increases in Naïve T-cell Number in
HIV-negative Healthy Young Adults
S Vlahakis,
E Tangalos, M McClees, et al
Abstract
-
Nelfinavir Pharmacokinetics (625-mg Tablets) during the Third
Trimester of Pregnancy and Post-partum
J Read, B
Best, A Stek, et al
Abstract
-
POSTER
High Prevalence of Primary Lamivudine and Nelfinavir Resistance
in HIV-1-infected Pregnant Women |
in the United Stated, 1998-2003
R Paredes, I
Cheng, D Kuritzke, et al
PDF Poster
Abstract
8th Int Congress on Drug Therapy in HIV
Infection
|
-
5-year outcome in 19 HIV1-positive children treated with 2 nucleoside
reverse transcriptase
inhibitors + nelfinavir as first line protease inhibitor
B Buchholz, S Hien, M Beicher, et al
Abstract
-
Why do patients continue on a non-boosted PI regimen? Data from a cohort of
1012 nelfinavir
(NFV)-treated patients
A Antela, JM Antunez, E Ortega, et al
Abstract
-
Influence of highly active antiretroviral therapy with nelfinavir on
endothelial cell-derived microparticles
in
human immunodeficiency virus-1-infected patients
OM Korzh, G Kotchuev, OO Pavlova , et al
Abstract
-
Role of circulating thrombomodulin level in latent progression of
atherosclerosis in human
immunodeficiency virus-1-infected patients receiving highly active
antiretroviral therapy with nelfinavir
I Korzh, V Nemtsova, I Fedotova , et al
Abstract
XVI
International AIDS Conference
|
-
No QT prolongation four nelfinavir clinical studies
Pun E., Petersen A., Thompson M., et al
Abstract
-
Results of a pilot study on nelfinavir ONLINE®, TDM assay of HIV
protease inhibitor nelfinavir
Burger D., Berg T., Teulen M., et al
Abstract
-
Satisfaction and symptom surveys reported with 625mg nelfinavir
tablets among HIV-infected
individuals previously receiving 250mg nelfinavir tablets
Abernathy K., Hardy H., Clincea R., et al
Abstract
-
Safety and gastrointestinal tolerability of 625mg Nelfinavir tablets
among HIV-Infected individuals
previously receiving 250mg Nelfinavir tablets
Abernathy K., Hardy H., Clincea R., Stanic A.
Abstract
-
The HIV protease inhibitors nelfinavir and saquinavir induce
epithelial apoptosis in normal and
malignant human colorectal mucosa and cancer cell lines
Lenzner L., Bode H., Krämer O.H., et al
Abstract
-
DEXA outcomes in antiretroviral-naive subjects randomized to
nelfinavir or efavirenz or both plus dual
nucleosides: long-term results from A5005s, a substudy of ACTG 384
Dubé M., Komarow L., Mulligan K., et al
Abstract-
Relationship between circulating thrombomodulin levels and latent
progression of atherosclerosis
in HIV-1-infected patients receiving highly active antiretroviral
therapy with nelfinavir
KorzhI., Nemtsova V., Fedotova I.
Abstract
M-A Khuong-Josses,
A Boussaïri
Abstract
NFV (625 mg new formulation) boosted with RTV once daily is not an option as
compared to twice
daily regimen.
Landman R,
Peytavin G, Descamps D, et al
Abstract
Reduced rates of viral load suppression at six to 12 months by saquinavir and
nelfinavir
are not
solely explained by reduced adherence to therapy.
Moore D, Hogg
R, Yip B, et al
Abstract
Influence of highly active antiretroviral therapy with nelfinavir on
endothelial cell-derived
microparticles in HIV-1-infected patients
Korzh O.
Abstract
Characteristics Of HIV-1 Genotyping Test After Failure With High Strengh
Scheme
With Nelfinavir As First Protease Inhibitor
Tupinambás U., Aleixo A., Greco D.
Abstract
Effects of highly active antiretroviral therapy (HAART) regimens containing
the protease
inhibitor (PI) nelfinavir on apoptosis of peripheral blood mononuclear cells.
Míró Ò., Villarroya J., López S., Garrabou G., et al
ck">
6th
International Workshop on Clinical
Pharmacology
of HIV Therapy |
DW Haas, L Smeaton, R Shafer, et al
Abstract
Does Nelfinavir Induce Lactose Intolerance?
A Andrade, C Cuffari, C Sears, C Flexner
Abstract
Role of
HIV-1 Minority Populations on Resistance Mutational Patterns Evolution after
Nelfinavir
Failure and
Susceptibility to Protease Inhibitors
A-G Marcelin , B
Roquebert , I Malet, et al
Abstract
CC
Lawrence, A Thomas, W Yuan, et al
Abstract
Comparison of the gastrointestinal tolerability and patient
preference for treatment with the
Roche Nelfinavir 625 mg and 250 mg (Viracept®) tablet formulations
M Johnson, L Nieto-Cisneros, A Horban, et
al
Abstract
Impact
of Nelfinavir-resistance mutations on the Human Immunodeficiency Virus type 1
with
subtype B and C proteases
LMF Gonzalez-Olivieri, R Brindeiro, M
Soares, et al
Abstract
The introduction of nelfinavir-containing antiretroviral therapy does not
increase the estimated
cardiovascular risk at 6 months in HIV-infected adults
E Martinez, P Viciana, F
Pulido, et al
Abstract
Effects
of highly active antiretroviral therapy with nelfinavir on immune activation and
reconstitution markers in HIV-1-infected patients
IV Korzh, IF Fedotova, VD
Nemtsova, et al
Abstract
An
analysis of nelfinavir adherence, resistance, and HIV viral load
AK Wutoh, M Daftary, Z Xue, EA Nwankwo
Abstract
Influence of Single-nucleotide polymorphisms of the multidrug resistance-1 gene
on export of
nelfinavir from lymphoblastoid cell lines and clinical response to
antiretroviral therapy in
Japanese patients infected with human immunodeficiency virus type 1
D Zhu, H Nakamura, M Goto, et al
Abstract
-
POSTER
Evaluation of HCV RNA and Liver Injury in HCV/HIV Co-infected
Patients Initiating Lopinavir/r or
Nelfinavir-based Therapy
KE Sherman, NJ Shire, P Cernohous, et al
 PDF
Poster
Abstract
-
POSTER
Sex and Weight as Covariates in the Pharmacokinetics of Efavirenz,
Indinavir, and Nelfinavir
J Hitti, S Rosenkranz, S Cohn. et al
 PDF
Poster
Abstract
|
|
|
Nelfinavir
Main Page
Main New/Newsworthy
